A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to T-cell Malignancies
Related studies linked through entity extraction aliases.
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2